EUCTR2016-002198-37-ES进行中（未招募）1 期
A single-center, randomized, open-label, 12 months study, with two parallel group to compare the efficacy of everolimus combination + tacrolimus in regression of left ventricular hypertrophy vs tacrolimus + mycophenolate mofetil in renal transplant patients in the maintenance phase
HOSPITAL UNIVERSITARI DE BELLVITGE - IDIBE0 个研究点开始时间: 2016年7月15日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •-Patient’s signed informed consent prior to any study-related procedure.
- •- Adult patients (> 18 years), renal transplant recipients of more than 1 year of evolution.
- •- Patients receiving maintenance immunosuppression with tacrolimus delayed release (Envarsus®) and MMF / MPA.
- •-Patients with Left Ventricular Hypertrophy detected by Cardio-NMR.
- •-Subjects with glomerular filtration rate >30 ml/min (calculated by CKD-EPI) and stable in the last two analytical determinations (variation <20%).
- •-No known contraindications to the use of Mtor inhibitors (previous intolerance, deep vein thrombosis , pulmonary embolism, proteinuria > 0.5 g/day)
- •-Patients with Hb levels = 11 gr/dl.
- •-Patients with blood pressure <140/90 mmHg in the hospital visits or <135/85 mmHg at home.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 20
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 20
排除标准
- •-Patient is currently receiving aldosterone blockers and/or ACEi and/or ARB.
- •-Presence of hyperdynamic arteriovenous fistula (non-distal AVF).
- •-Proteinuria > 0.5 g/day in 24 hour urine.
- •- Cardiovascular event (hemorrhagic or ischemic stroke, acute myocardial infarction with or without revascularization, amputation, lower limb ischemia) in the 6 months prior to the inclusion in the study.
- •- Patient who presented severe chronic rejection (> IA according to Banff criteria) and / or presence of high immunological risk at the time of renal transplantation and / or inclusion in the study (presence of DSA)
- •- Patient with recurrence of glomerulonephritis after renal transplantation.
- •- Female subjects of child bearing potential who are pregnant or breast feeding, or who are unable or unwilling to use a medically acceptable form of contraception during their participation in the study.
- •-Any other medical condition that, in the opinion of the investigator, based on the count or review of medical records, could affect the completion of the study, including, but not limited to, visual problems or cognitive impairment.
- •-Recipient of a multi-organ transplant or an ABO incompatible kidney.
- •-Nuclear magnetic resonance contraindication (pacemakers, metal implants, etc).
- •-Patient is receiving other immunosuppression treatment than Envarsus® and MMF/MPA.
- •-Known allergy to iodinated contrast agents
研究者
相似试验
进行中（未招募）
1 期
A 12-month, multicenter, open label, randomized, controlled study to evaluate the efficacy, tolerability and safety of early introduction of everolimus, reduced CNI, and early steroid elimination compared to standard CNI, mycophenolate mofetil and steroid regimen in paediatric renal transplant recipients with a 24-month additional safety follow-up.Prevention of acute rejection in paediatric recipients of a renal transplantMedDRA version: 14.1Level: PTClassification code 10038533Term: Renal transplantSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 14.1Level: LLTClassification code 10023438Term: Kidney transplantSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2010-024381-21-ITOVARTIS FARMA106
进行中（未招募）
1 期
Study to evaluate renal function of everolimus plus tacrolimus in liver transplant patientsliver transplantationMedDRA version: 20.0Level: LLTClassification code 10024716Term: Liver transplantationSystem Organ Class: 100000004865EUCTR2011-003118-17-DEovartis Pharma GmbH
进行中（未招募）
不适用
A 12-month, multi-center, randomized, open-label non-inferiority study of renal function and efficacy comparing concentration-controlled Certican® (1.5 mg/day starting dose) with reduced Neoral® dose versus MMF with standard Neoral® dose in de novo heart transplant recipients. - RAD2411EUCTR2004-001052-36-DEovartis Pharma Services AG176
进行中（未招募）
不适用
A 12-month, multi-center, randomized, open-label non-inferiority study of renal function and efficacy comparing concentration-controlled Certican® (1.5 mg/day starting dose) with reduced Neoral® dose versus MMF with standard Neoral® dose in de novo heart transplant recipients. - RAD2411EUCTR2004-001052-36-ESovartis Farmacéutica S.A176
进行中（未招募）
不适用
A 12-month, multicenter, randomized, open-label non-inferiority study of renal function and efficacy comparing concentration-controlled Certican (1.5 mg/day starting dose) with reduced Neoral dose versus MMF with standard Neoral dose in de novo heart transplant recipientsProphylaxis of organ rejection in adult patients at low to moderate immunological risk receiving an allogeneic cardiac transplant. The drug should be used in combination with ciclosporin for microemulsion and corticosteroids.MedDRA version: 6.1Level: PTClassification code 10019315EUCTR2004-001052-36-ITOVARTIS FARMA